Blog Posts

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was
Read More »

Sentry Data Systems Is the Latest 340B TPA to Change Hands

“Sentry looks forward to continuing to innovate and grow with its new partnership with Craneware," Sentry CEO Travis Leonardi said about his company's sale this week.
Healthcare data analytics company Craneware is buying 340B third-party administrator Sentry Data Systems, the latest in a series of 340B TPA acquisitions.

Please Login or Become a Paid Subscriber to View this Content

Read More »

CMS Seeks Medicare DSH Calculation Change That Could Disqualify Some Hospitals From 340B

CMS's proposed change to the Inpatient Prospective Payment Systems could cause some hospitals to be disqualified from the 340B program.
The U.S. Centers for Medicare & Medicaid Services is proposing a change to the Medicare disproportionate share hospital (DSH) payment methodology that could cause some hospitals in seven states to be disqualified from the 340B program.
Read More »

In First of Its Kind Legislation, Louisiana Cracks Down on White-Bagging Requirements

Louisiana has just enacted a law stopping insurers or their pharmacy benefit managers from requiring or pressuring in-network providers to accept "white bagging" of physician-administered drugs. | Shutterstock
Louisiana Gov. John Bel Edwards (D) has signed legislation stopping insurers or their pharmacy benefit managers from requiring or pressuring in-network providers to obtain physician-administered drugs exclusively from pharmacies in the insurer’s network.

Please Login or

Read More »

More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows

More than one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution during the past two years, an analysis of campaign finance records by news organization STAT found.
In the last two years, over one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution, news organization STAT reports.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Becerra’s Message to Pharma on 340B: “You Violate the Law, You Pay the Consequences”

HHS Secretary Xavier Becerra told a Senate committee this morning his department has sent drug companies "a clear message" that if they violate the 340B statute, they will "pay the consequences."
U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a U.S. Senate Appropriations subcommittee this morning that his department has sent “a clear message” to six drug manufacturers denying 340B discounts on drugs shipped to contract pharmacies “that we
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed mainly in Europe as an over the counter sedative and morning sickness medicine for
Read More »